Customized biofilm device for antibiofilm and antibacterial screening of newly developed nanostructured silver and zinc coatings.
Antibacterial
Antibiofilm
Biocompatibility
Calgary Biofilm Device
Ionized Jet Deposition
Metal coatings
Journal
Journal of biological engineering
ISSN: 1754-1611
Titre abrégé: J Biol Eng
Pays: England
ID NLM: 101306640
Informations de publication
Date de publication:
06 Mar 2023
06 Mar 2023
Historique:
received:
30
10
2022
accepted:
19
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Bacterial colonisation on implantable device surfaces is estimated to cause more than half of healthcare-associated infections. The application of inorganic coatings onto implantable devices limits/prevents microbial contaminations. However, reliable and high-throughput deposition technologies and experimental trials of metal coatings for biomedical applications are missing. Here, we propose the combination of the Ionized Jet Deposition (IJD) technology for metal-coating application, with the Calgary Biofilm Device (CBD) for high-throughput antibacterial and antibiofilm screening, to develop and screen novel metal-based coatings. The films are composed of nanosized spherical aggregates of metallic silver or zinc oxide with a homogeneous and highly rough surface topography. The antibacterial and antibiofilm activity of the coatings is related with the Gram staining, being Ag and Zn coatings more effective against gram-negative and gram-positive bacteria, respectively. The antibacterial/antibiofilm effect is proportional to the amount of metal deposited that influences the amount of metal ions released. The roughness also impacts the activity, mostly for Zn coatings. Antibiofilm properties are stronger on biofilms developing on the coating than on biofilms formed on uncoated substrates. This suggests a higher antibiofilm effect arising from the direct contact bacteria-coating than that associated with the metal ions release. Proof-of-concept of application to titanium alloys, representative of orthopaedic prostheses, confirmed the antibiofilm results, validating the approach. In addition, MTT tests show that the coatings are non-cytotoxic and ICP demonstrates that they have suitable release duration (> 7 days), suggesting the applicability of these new generation metal-based coatings for the functionalization of biomedical devices. The combination of the Calgary Biofilm Device with the Ionized Jet Deposition technology proved to be an innovative and powerful tool that allows to monitor both the metal ions release and the surface topography of the films, which makes it suitable for the study of the antibacterial and antibiofilm activity of nanostructured materials. The results obtained with the CBD were validated with coatings on titanium alloys and extended by also considering the anti-adhesion properties and biocompatibility. In view of upcoming application in orthopaedics, these evaluations would be useful for the development of materials with pleiotropic antimicrobial mechanisms.
Sections du résumé
BACKGROUND
BACKGROUND
Bacterial colonisation on implantable device surfaces is estimated to cause more than half of healthcare-associated infections. The application of inorganic coatings onto implantable devices limits/prevents microbial contaminations. However, reliable and high-throughput deposition technologies and experimental trials of metal coatings for biomedical applications are missing. Here, we propose the combination of the Ionized Jet Deposition (IJD) technology for metal-coating application, with the Calgary Biofilm Device (CBD) for high-throughput antibacterial and antibiofilm screening, to develop and screen novel metal-based coatings.
RESULTS
RESULTS
The films are composed of nanosized spherical aggregates of metallic silver or zinc oxide with a homogeneous and highly rough surface topography. The antibacterial and antibiofilm activity of the coatings is related with the Gram staining, being Ag and Zn coatings more effective against gram-negative and gram-positive bacteria, respectively. The antibacterial/antibiofilm effect is proportional to the amount of metal deposited that influences the amount of metal ions released. The roughness also impacts the activity, mostly for Zn coatings. Antibiofilm properties are stronger on biofilms developing on the coating than on biofilms formed on uncoated substrates. This suggests a higher antibiofilm effect arising from the direct contact bacteria-coating than that associated with the metal ions release. Proof-of-concept of application to titanium alloys, representative of orthopaedic prostheses, confirmed the antibiofilm results, validating the approach. In addition, MTT tests show that the coatings are non-cytotoxic and ICP demonstrates that they have suitable release duration (> 7 days), suggesting the applicability of these new generation metal-based coatings for the functionalization of biomedical devices.
CONCLUSIONS
CONCLUSIONS
The combination of the Calgary Biofilm Device with the Ionized Jet Deposition technology proved to be an innovative and powerful tool that allows to monitor both the metal ions release and the surface topography of the films, which makes it suitable for the study of the antibacterial and antibiofilm activity of nanostructured materials. The results obtained with the CBD were validated with coatings on titanium alloys and extended by also considering the anti-adhesion properties and biocompatibility. In view of upcoming application in orthopaedics, these evaluations would be useful for the development of materials with pleiotropic antimicrobial mechanisms.
Identifiants
pubmed: 36879323
doi: 10.1186/s13036-023-00326-y
pii: 10.1186/s13036-023-00326-y
pmc: PMC9987098
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
© 2023. The Author(s).
Références
J Med Microbiol. 2021 May;70(5):
pubmed: 33961541
Micron. 2017 Sep;100:60-72
pubmed: 28514702
J Appl Biomater Funct Mater. 2021 Jan-Dec;19:22808000211040304
pubmed: 34409896
J Mater Sci Mater Med. 2012 Aug;23(8):1983-90
pubmed: 22584824
Microb Biotechnol. 2017 Sep;10(5):1062-1065
pubmed: 28745454
J Nanobiotechnology. 2018 Jan 31;16(1):10
pubmed: 29386060
Nanoscale. 2018 Mar 8;10(10):4927-4939
pubmed: 29480295
J Prosthodont. 2021 Jun;30(5):440-446
pubmed: 32902065
Nanomedicine. 2011 Apr;7(2):184-92
pubmed: 21034861
Nanomaterials (Basel). 2022 Jul 14;12(14):
pubmed: 35889626
Clin Microbiol Infect. 2016 Aug;22(8):732.e1-8
pubmed: 27181408
Injury. 2006 May;37 Suppl 2:S59-66
pubmed: 16651073
J Biomed Mater Res B Appl Biomater. 2016 Oct;104(7):1359-65
pubmed: 26698606
J Endod. 2014 Feb;40(2):285-90
pubmed: 24461420
ACS Cent Sci. 2022 May 25;8(5):546-561
pubmed: 35647287
Nat Rev Microbiol. 2013 Jun;11(6):371-84
pubmed: 23669886
Front Microbiol. 2016 Nov 16;7:1831
pubmed: 27899918
ACS Nano. 2009 Jun 23;3(6):1357-64
pubmed: 19545167
J Hosp Infect. 2017 May;96(1):1-15
pubmed: 28410761
Mater Sci Eng C Mater Biol Appl. 2021 Apr;123:112031
pubmed: 33812646
J Nanobiotechnology. 2017 Oct 3;15(1):65
pubmed: 28974225
Surg Infect (Larchmt). 2013 Aug;14(4):345-51
pubmed: 23859684
Biochem Biophys Res Commun. 2013 Nov 29;441(4):947-52
pubmed: 24239884
BMC Infect Dis. 2020 May 12;20(1):337
pubmed: 32398027
Biomater Investig Dent. 2020 Jul 23;7(1):105-109
pubmed: 32939454
Front Med (Lausanne). 2020 Oct 26;7:513242
pubmed: 33195289
Int J Nanomedicine. 2019 Dec 02;14:9395-9410
pubmed: 31819439
Sci Rep. 2022 Feb 16;12(1):2658
pubmed: 35173244
Metallomics. 2018 Apr 25;10(4):557-564
pubmed: 29637212
Bioact Mater. 2021 Jan 05;6(8):2629-2642
pubmed: 34027240
Int J Mol Sci. 2019 Aug 03;20(15):
pubmed: 31382580
Mater Sci Eng C Mater Biol Appl. 2019 Jun;99:853-862
pubmed: 30889760
Crit Rev Microbiol. 2017 May;43(3):313-351
pubmed: 27868469
Nanoscale. 2013 Aug 21;5(16):7328-40
pubmed: 23821237
EFORT Open Rev. 2019 Nov 5;4(11):633-639
pubmed: 31754470
J Clin Microbiol. 1999 Jun;37(6):1771-6
pubmed: 10325322
Trends Microbiol. 2020 Aug;28(8):668-681
pubmed: 32663461
ACS Omega. 2018 Jun 30;3(6):6456-6464
pubmed: 30023948
Adv Colloid Interface Sci. 2018 Nov;261:1-14
pubmed: 30376953
Injury. 2017 Mar;48(3):599-607
pubmed: 28088378
Shock. 2016 Dec;46(6):597-608
pubmed: 27454373
J Bacteriol. 2008 Aug;190(16):5690-8
pubmed: 18556793
FEMS Immunol Med Microbiol. 2012 Jul;65(2):183-95
pubmed: 22444301
J Clin Microbiol. 2010 May;48(5):1720-5
pubmed: 20335421
J Hosp Infect. 2006 Feb;62(2):174-80
pubmed: 16343691
Mater Sci Eng C Mater Biol Appl. 2020 Aug;113:110998
pubmed: 32487406
Curr Drug Targets. 2012 Aug;13(9):1121-30
pubmed: 22664072
J Med Microbiol. 2007 Dec;56(Pt 12):1581-1588
pubmed: 18033823
Nat Rev Microbiol. 2007 Dec;5(12):928-38
pubmed: 17940533